Today, we announced an exclusive licencing agreement with Eli Lilly and Company granting certain rights to develop and commercialise clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody. CSL...
AI: Exclusive licensing agreement with major pharma company Eli Lilly for clazakizumab (anti-IL-6 monoclonal antibody). CSL retains rights for cardiovascular applications in ESKD patients. Strategic partnership with concrete therapeutic focus.